doi: 10.1055/s-2006-931485.
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia
Affiliations
- PMID: 16508892
- DOI: 10.1055/s-2006-931485
Item in Clipboard
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia
Pharmacopsychiatry.
2006 Feb.
Abstract
Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.
Similar articles
-
Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.Clin Neuropharmacol. 2011 Jul-Aug;34(4):135-6. doi: 10.1097/WNF.0b013e31822046bc. Clin Neuropharmacol. 2011. PMID: 21768798
-
Aripiprazole as a dopamine partial agonist: positive and negative effects.J Clin Psychopharmacol. 2006 Feb;26(1):101-3. doi: 10.1097/01.jcp.0000196417.44847.0b. J Clin Psychopharmacol. 2006. PMID: 16415723 No abstract available.
-
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.Expert Opin Investig Drugs. 2003 Apr;12(4):655-62. doi: 10.1517/13543784.12.4.655. Expert Opin Investig Drugs. 2003. PMID: 12665420 Review.
-
[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].Ann Pharm Fr. 2009 Sep;67(5):310-9. doi: 10.1016/j.pharma.2009.05.004. Epub 2009 Jul 18. Ann Pharm Fr. 2009. PMID: 19695367 Review. French.
-
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.Arch Gen Psychiatry. 2003 Jul;60(7):681-90. doi: 10.1001/archpsyc.60.7.681. Arch Gen Psychiatry. 2003. PMID: 12860772 Clinical Trial.
Cited by
-
Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.J Neural Transm (Vienna). 2018 Aug;125(8):1203-1216. doi: 10.1007/s00702-017-1837-1. Epub 2018 Jan 5. J Neural Transm (Vienna). 2018. PMID: 29305656 Review.
-
Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder.CNS Drugs. 2008;22(4):335-52. doi: 10.2165/00023210-200822040-00005. CNS Drugs. 2008. PMID: 18336061 Review.
-
Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents.Adolesc Health Med Ther. 2014 Nov 27;5:211-21. doi: 10.2147/AHMT.S50015. eCollection 2014. Adolesc Health Med Ther. 2014. PMID: 25473324 Free PMC article. Review.
-
Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.Drugs. 2012 Jan 1;72(1):133-62. doi: 10.2165/11208320-000000000-00000. Drugs. 2012. PMID: 22191800 Review.
-
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.J Neural Transm (Vienna). 2009 Jul;116(7):881-4. doi: 10.1007/s00702-009-0231-z. Epub 2009 May 12. J Neural Transm (Vienna). 2009. PMID: 19533295 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
